Anti-DLL3 antibodies and uses thereof

TW202637611APending Publication Date: 2026-09-16LEPU BIOPHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115121412
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-11
Filing Date
2024-09-20
Publication Date
2026-09-16

Smart Images

  • Figure TWG2TA001077415_001
    Figure TWG2TA001077415_001
  • Figure TWG2TA001077415_002
    Figure TWG2TA001077415_002
  • Figure TWG2TA001077415_003
    Figure TWG2TA001077415_003
Patent Text Reader

Abstract

This disclosure provides anti-DLL3 antibodies, including murine antibodies, humanized antibodies, and those with further optimized CDR sequences. The newly disclosed antibodies have excellent binding specificity and improved activities as compared to other anti-DLL3 antibodies under development.
Need to check novelty before this filing date? Find Prior Art